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were done immediately after the TAVI procedure. Trans-femoral TAVI’s were
associated with higher risk (OR 8.6, 95% CI 3.1 – 28.3) of developing permanent
heart block compared to transapical route (OR 2.4, 95% CI, 1.3 – 4.3). Core Valve
use was associated with a higher risk of developing permanent heart block (OR 2.4,
95% CI 1.6 – 3.6) than Edward Sapiens Valve (OR 1.9, 95% CI 1.2 – 2.8)
compared to SAVR.
Conclusions: Patients undergoing minimally invasive TAVI procedure have a four
times higher risk of developing heart block needing pacemaker implantation compared
to patients undergoing SAVR procedure.
TCT-771
Comparison of post TAVR paravalvular regurgitation between Edwards
SAPIEN 3 and Edwards SAPIEN XT; early, single center experience
Vasileios F. Panoulas1, Gennaro Giustino2, Azeem Latib2, Matteo Montorfano2,
Alaide Chieffo2, Paola Spatuzza2, Maurizio Taramasso2, Filippo Figini2,
Eustachio Agricola2, Pietro Spagnolo2, Ottavio Alﬁeri2, Antonio Colombo3
1Imperial College London, London, Greater London, UK, 2San Raffaele Scientiﬁc
Institute, Milan, Italy, 3EMO GVM Centro Cuore Columbus/San Raffaele Hospital,
Milan, Italy
Background: The Edwards SAPIEN 3 (Edwards Lifesciences, Irvine, CA, USA)
transcatheter heart valve ( S3 THV) incorporates a paravalvular sealing system with
an active 3-dimensional coaxial positioning. No comparisons in clinical practice
have been performed with its predecessor, SAPIEN XT (SXT) with regards to
paravalvular aortic regurgitation (PAR), a predictor of future mortality in TAVR
patients.
Methods: All patients implanted with an Edwards XT or S3 THV, from January 2013
to April 2014 in San Rafaelle Scientiﬁc Institute, Milan, Italy, were included in the
current study. PAR was assessed using aortography and transthoracic echocardiog-
raphy after TAVR.
Results: A total of 61 Edwards SAPIEN transfemoral TAVR were performed (14
S3 and 47 SXT). With the exception of higher percentage of baseline moderate/
severe AR in the Sapiens 3 group (20% SXT vs. 64.3% S3, p¼0.002) baseline
demographics did not differ signiﬁcantly between the groups (Table 1). Balloon
aortic valve predilatation was performed more frequently in the SXT group (95.7%
vs. 28.6%, p< 0.001). In both groups similar valve sizes were used (23/26/29mm:
38.3%/48.9%/12.8% S3 vs. 37.7%/35.7%/28.6% SXT, p0.355). Similar was also
the percentage of postdilatation (23.4 % SXT vs. 21.4% S3, p¼0.877). Final
aortography revealed non/trace PAR in 92.9% S3 vs. 17.9% SXT; mild in 7.1%
S3 vs. 67.7% SXT and moderate/severe in 0% S3 and 15.4% SXT (p< 0.001).
Similar results were obtained when comparing ﬁnal echocardiographic assessment
for PAR. There was a trend for a higher device success (as per VARC-2) amongst
S3 patients (100% vs. 83%, p¼0.180).Baseline
Characteristics Total(N¼61)
Edwards
SAPIEN XT
(N¼47)
Edwards
SAPIEN 3
(N¼14)
P-
value
Age (years) 80.27.0 80.477.0 79.367.3 0.607
Female gender 45.90% 51.10% 28.60% 0.138
Diabetes Mellitus 26.20% 27.70% 21.40% 0.642
Previous myocardial
infarction
9.80% 10.60% 7.10% 0.7
Previous PCI 21.30% 21.30% 21.40% 0.99
Previous CABG 21.30% 19.10% 28.60% 0.45
Logistic EuroSCORE
(%)
18.614.9 18.314.9 19.815.4 0.746
STS Score (%) 5.4 (3.6 to
12.0)
6.3 (3.9 to
13.7)
4.4 (3.2 to
10.0)
0.11
Left ventricular
ejection fraction (%)
53.213.3 52.113.7 56.8 0.25
Mean aortic
annulus (mm) CT
23.91.8 23.81.7 24.52.2 0.214
Minimum ilio-
femoral diameter
(mm)
7.01.2 7.21.2 6.61.0 0.156
Aortic valve area
(cm2)
0.701.2 0.650.16 0.790.19 0.016
Aortic mean
gradient (mmHg)
50.314.5 51.215.6 47.610.6 0.426
Aortic regurgitation
 moderate
30.50% 20% 64.30% 0.002
Mitral regurgitation
 moderate
32.20% 33.30% 28.60% 0.739
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regurgitation when compared to its predecessor SXT.
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Background: Procedural technical features of CoreValve implantation have been
shown to affect the short and long-term outcome after Transcatheter Aortic Valve
Implantation (TAVI). The aim of this study was to evaluate the impact of Cor-
eValve implantation depth on the short-term hemodynamic and procedural
characteristics.
Methods: From June 2008 until February 2013, patients who had undergone TAVI
with the CoreValve device, were retrospectively studied. The device implantation
depth was evaluated in ofﬂine analysis by measuring the distance between the lowest
coronary cusp calcium border, as depicted in the post-implantation aortography, and
the lowest edge of the device frame (smaller measured distance indicating higher
implantation depth, see image). The aortic valve regurgitation (AR) was evaluated
after TAVI and classiﬁed as none, mild and moderate. Finally, the necessity of post-
implantation balloon dilatation in order to achieve a better valve expansion was
recorded.
Results: A total of 119 patients (mean age 80.65.3 yrs, 62 males) were ﬁnally
enrolled. The implantation was performed either transfemoraly, or through subcla-
vian route (12 patients). A statistically signiﬁcant difference was found for the
implantation depth between the three post-TAVI aortic regurgitation classiﬁcations
(8.12mm for none AR, 7.95mm for mild and 6.27mm for moderate AR, p¼0.046),
indicating increased AR with higher device implantation. Similarly, patients who
underwent balloon post-dilatation, had statistical signiﬁcant higher implantation
depth compared with those who didn’t (6.393.2mm vs 8.142.5mm, p¼0.012).
The implantation depth remained an independent predicting factor of balloon post-
dilatation necessity in multivariate logistic regression [OR:0.775 (0.64-0.938),
p¼0.009].
Conclusions: The CoreValve device implantation depth is strongly correlated with the
post-implantation observed aortic regurgitation, as well as with the necessity of
balloon post-dilatation. It seems that, concerning hemodynamic short-term outcome,
operators should be even more careful in device implantation depth ensuring the
optimal positioning.
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Background: In-stent pre-cusp ﬂow acceleration and its importance in the accurate
echo assessment of the Sapien valve are well recognized with stent and valve cusps
contributing to overall valve gradients. The echo ﬂow features of the CoreValve have
not been previously reported.
Methods: Pre-stent (P-S) and in-stent pre-cusp (I-SPC) CoreValve velocities were
measured in 17 consecutive CoreValve pts. Valve sizes (mm) were 26(n¼4),
29(n¼6), and 31(n¼7). Pulsed-wave (PW) Doppler velocity time integral (VTI) was
recorded with sample volume placement at 2 levels: immediately apical to the stent
(P-S) and within the stent just apical to the valve cusps (I-SPC). Effective oriﬁce
area (EOA) ¼ (LVOT CSA X LVOT VTI)/AV VTI and Doppler velocity index
(DVI) ¼ LVOT VTI/AV VTI were calculated using both the P-S and I-SPC for
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